Exclusive Summary

• - Fully registered across EU-27 plus Singapore, offering high compliance credentials and immediate access to hospital tenders and distribution.
• - Stable global inpatient demand for IV PPIs in UGIB, ICU/post-op and NPO settings underpins consistent volume in hospital channels.
• - Guidelines endorse high-dose IV PPI after endoscopic hemostasis; pantoprazole is preferred with clopidogrel due to fewer CYP2C19 interactions.
• - Patent long expired with broad genericization; pricing typically 80–95% below originator, fitting tender-driven, price-sensitive markets.
• - EU-standard manufacturing, PV system and multi-region registration enable reliance-based approvals and rapid expansion with resilient supply.